<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144764">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02106585</url>
  </required_header>
  <id_info>
    <org_study_id>AT251-U-13-001</org_study_id>
    <nct_id>NCT02106585</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects</brief_title>
  <official_title>Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and PK (Pharmacokinetics)
      of single oral doses of JTT-251 in healthy and type 2 diabetes mellitus subjects and to
      evaluate the effect of food on the PK of JTT-251 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs and 12 lead ECGs</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration)</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (elimination half-life)</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the concentration-time curve)</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>fe(total) (fraction of systemically available drug excreted into the urine over entire collection interval)</measure>
    <time_frame>1 week</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">94</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dose 1 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 6 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 7 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 8 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 9 JTT-251 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, single dose in fasted or fed condition followed by a single dose in the alternate fed or fasted condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTT-251 or Placebo</intervention_name>
    <description>Subjects will receive JTT-251 or Placebo</description>
    <arm_group_label>Dose 1 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 2 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 3 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 4 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 5 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 6 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 7 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 8 JTT-251 or Placebo</arm_group_label>
    <arm_group_label>Dose 9 JTT-251 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy Subject Cohorts:

          -  Healthy male or female subjects

          -  Body Mass Index (BMI) between 19.0 and 31.0 kg/m2 (inclusive)

        Type 2 Diabetic Subject Cohorts:

          -  Male or female Type 2 diabetic subjects diagnosed for at least 3 months

          -  BMI between 25 and 40 kg/m2 (inclusive)

          -  Have a glycosylated hemoglobin (HbA1c) of &gt;6.5% to ≤10.9% (inclusive) if treatment
             naïve with respect to hypoglycemic agents OR &gt;6.5% to ≤10.0% (inclusive) if treated
             with metformin

        Exclusion Criteria:

        Healthy Subject Cohorts:

          -  Known clinically relevant history or presence of significant respiratory,
             gastrointestinal, renal, hepatic, hematological, lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             metabolic, and dermatological or connective tissue disease

          -  Subjects with a systolic blood pressure &gt;150 mmHg and/or diastolic blood pressure &gt;90
             mmHg

        Type 2 Diabetic Subject Cohorts:

          -  Subjects with a known medical history or presence of type 1 diabetes mellitus

          -  Subjects with known medical history of acute metabolic diabetic complications

          -  Subjects with uncontrolled hypertension (systolic blood pressure &gt;160 mmHg and/or
             diastolic blood pressure &gt;95 mmHg with documented ongoing treatment)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hideyuki Yamamoto</last_name>
    <role>Study Chair</role>
    <affiliation>Akros Pharma Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hideyuki Yamamoto</last_name>
    <phone>609-919-6111</phone>
    <email>yamamotoh@akrospharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Food-effect</keyword>
  <keyword>Diabetes</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
